Literature DB >> 1873308

Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography.

T Wikberg1.   

Abstract

An ion-pair reversed-phase liquid chromatographic method for the simultaneous determination of levodopa, 3-O-methyldopa, 3,4-dihydroxyphenylacetic acid, homovanillic acid and carbidopa in plasma designed for clinical trials performed to study the effect of peripheral catechol-O-methyltransferase inhibitors on the metabolism of levodopa is described. The high sample throughput of over 50 samples per day of the method makes it ideal for the assay of the large number of samples encountered in clinical trials. After protein precipitation with perchloric acid the analytes are completely separated within 15 min and determined down to a plasma concentration of 20 ng ml-1 using amperometric detection at 800 mV relative to an Ag/AgCl reference electrode. For all analytes the within-day precision defined as a relative standard deviation (n = 8) is lower than 7 and 3% at plasma concentrations of 20 and 40 ng ml-1, respectively. As the method is specific and highly reproducible, the most important factor affecting accuracy is the stability of the analytes during storage and analysis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873308     DOI: 10.1016/0731-7085(91)80140-5

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.

Authors:  Lisa F Potts; Eun S Park; Jong-Min Woo; Bhagya L Dyavar Shetty; Arun Singh; Steven P Braithwaite; Michael Voronkov; Stella M Papa; M Maral Mouradian
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

2.  The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Authors:  P Piccini; D J Brooks; K Korpela; N Pavese; M Karlsson; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

Review 3.  Determination of levodopa by chromatography-based methods in biological samples: a review.

Authors:  Ruiqi Jiang; Jiayu Yang; Shenghui Mei; Zhigang Zhao
Journal:  Anal Sci       Date:  2022-06-17       Impact factor: 1.967

4.  COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.

Authors:  T Keränen; A Gordin; M Koulu; M Scheinin; S Antila; S Sundberg; T Wikberg
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.

Authors:  N Simon; F Viallet; A Boulamery; A Eusebio; D Gayraud; J-P Azulay
Journal:  Eur J Clin Pharmacol       Date:  2016-03-03       Impact factor: 2.953

6.  Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.

Authors:  H M Ruottinen; U K Rinne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

7.  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Authors:  Helena Heikkinen; Anu Varhe; Tarmo Laine; Jaakko Puttonen; Marjo Kela; Seppo Kaakkola; Kari Reinikainen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

8.  Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.

Authors:  V V Myllylä; K A Sotaniemi; A Illi; K Suominen; T Keränen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.